Vioxx should be allowed back on the market advises expert panel.
作者信息
Sibbald Barbara
出版信息
CMAJ. 2006 Aug 1;175(3):234. doi: 10.1503/cmaj.060821.
Abstract
摘要
相似文献
1
Vioxx should be allowed back on the market advises expert panel.
CMAJ. 2006 Aug 1;175(3):234. doi: 10.1503/cmaj.060821.
2
Health Canada lukewarm on Vioxx panel findings.
CMAJ. 2005 Aug 16;173(4):350. doi: 10.1503/cmaj.050901.
3
Life after Vioxx.
Newsweek. 2005 Jan 31;145(5):40-1.
4
The Vioxx fallout.
Minn Med. 2005 Mar;88(3):26-30.
5
Some key points emerging from the COX-2 controversy.
Pharmacoepidemiol Drug Saf. 2005 Mar;14(3):145-7. doi: 10.1002/pds.1076.
6
Balancing the cyclooxygenase portfolio.
CMAJ. 2006 May 23;174(11):1581-2. doi: 10.1503/cmaj.060471.
7
The COX-2 inhibitors--an update.
Am Heart J. 2006 Aug;152(2):197-9. doi: 10.1016/j.ahj.2006.05.022.
8
The withdrawal of rofecoxib.
Pharmacoepidemiol Drug Saf. 2005 Mar;14(3):213-7. doi: 10.1002/pds.1077.
9
A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.
Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1172-80. doi: 10.1002/pds.1994.
10
Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?
Can Fam Physician. 2005 Feb;51(2):212-3.
引用本文的文献
1
Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors.
Rheumatology (Oxford). 2023 Dec 1;62(12):3773-3775. doi: 10.1093/rheumatology/kead388.
Zotero 插件